Investors

Share Information

Number of shares: 7,183,168

Stock option plans total: 1,436,401 (see below for details)

Remaining total amount of option rights: 1,352,722

Option schemeSubscription price/shareMaximum amount of option rightsRemaining amount of option rightsSubscription period
2016CEUR 23.00556 shares556 shares1 July 2020 - 15 December 2025
2020AEUR 2.00163,001 shares80,786 shares

1 July 2022 - 15 December 2027

For 22,257 of the stock options: 1 July 2026 - 15 December 2027

2020BEUR 7.00206,011 shares206,011 shares

1 July 2023 - 15 December 2028

For 56,643 of the stock options: 1 July 2026 - 15 December 2028

2020CEUR 4.87213,819 shares212,409 shares

1 July 2024 - 15 December 2029

For 57,956 of the stock options: 1 July 2026 - 15 December 2029

2023AEUR 3.63229,294 shares229,294 shares1 July 2025 - 15 December 2030
2023BEUR 2.29255,583 shares255,583 shares1 July 2026 - 15 December 2031
2023CEUR 8.28255,583 shares255,583 shares1 July 2027 - 15 December 2032
2023HEUR 3.6337,500 shares37,500 shares1 July 2024 - 15 December 2029
2024HEUR 2.3037,500 shares37,500 shares1 July 2025 - 15 December 2030
2025HEUR 7.5637,500 shares37,500 shares1 July 2026 - 15 December 2031

 

Other

 Maximum amount of special rightsPrice per shareMaturity Date
Brainlab Warrants790,000EUR 5.0031 March 2027

 

Board of Directors authorizations outstanding total: 1,401,861 shares (see below extracts from AGM 2021 and AGM 2025 decisions; numbers and prices of shares adjusted according to the 2021 reverse split)

 

THE 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS AUTHORIZED THE BOARD OF DIRECTORS TO DECIDE ON SHARE ISSUES AS WELL AS ISSUES OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES, PURSUANT TO CHAPTER 10 OF THE COMPANIES ACT, AS FOLLOWS:

The shares issued under the authorisation are new or those in the Company’s possession. Based on and within the limits of this authorisation, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 the Companies Act complementing or replacing issuance(s) of shares.

The new shares can also be issued to the Company itself free of charge. Share issue against payment and without payment: New shares may be issued, and treasury shares held by the Company may be transferred either against payment (Share issue against payment) or free of charge (Share issue without payment). A directed share issue can only be without payment if there is a particularly weighty financial reason for it from the Company’s point of view and taking into account the interests of all its shareholders.

Under the authorisation, a maximum of 55,000 shares may be issued, which corresponds to approximately 0,82% percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company. 

The shares, option rights and/or other special rights entitling to shares can be issued in one or more tranches.

The Board of Directors is authorised to resolve on all terms for the share issues and the terms for the granting of the option rights and other special rights entitling to shares. The Board of Directors is authorised to resolve on a directed share issue and issue of the special rights entitling to shares in deviation from the shareholders’ preemptive right, provided that there is a weighty financial reason for the Company to do so.

The authorisation is valid for five (5) years from the decision of the Annual General Meeting of Shareholders. The authorisation may be used for the implementation of the RSU plan for the members of the Board of Director’s and for the long-term incentive plans for the management and the personnel of the Company. The authorisation can also be used for incentive arrangements and payment of the Board fees.

 

THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS AUTHORIZED THE BOARD OF DIRECTORS TO DECIDE ON SHARE ISSUES AS WELL AS ISSUES OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES, PURSUANT TO CHAPTER 10 OF THE COMPANIES ACT, AS FOLLOWS:

Right to shares:

New shares may be issued and the Company’s own shares transferred 

  • to the Company's shareholders in proportion to their current shareholdings in the Company; or
  • deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as the use of shares as consideration for possible acquisitions or other arrangements related to the company's business or financing of investments. 

The new shares can also be issued to the Company itself free of charge. Share issue against payment and without payment: New shares may be issued and treasury shares held by the Company may be transferred either against payment (Share issue against payment) or free of charge (Share issue without payment). A directed share issue can only be without payment if there is a very serious financial reason for it from the Company’s point of view and taking into account the interests of all its shareholders.

Maximum number of shares: 

Pursuant to the authorisation, the Board of Directors is entitled to decide on the issuance of new shares and/or the transfer of the Company’s own shares so that the total number of issued and/or transferred shares does not exceed 1,400,000 shares, which corresponds to approximately 16.35 percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company.

Issuance of special rights: 

The Board of Directors may issue special rights referred to in Chapter 10, Section 1 of the Companies Act, which entitle the holder to receive new shares or the Company’s own shares in against payment. The right may also be granted to the Company’s creditor in such a way that the right is subject to the condition that the creditor’s claim is used to set off the share subscription price (convertible bond). 

The number of new shares to be subscribed to under the special rights granted by the Company and the number of treasury shares to be transferred held by the Company may not exceed a total of 1,400,000, which is included in the maximum number mentioned in the “Maximum number of shares” -section above. 

Recording of the subscription price in the balance sheet: 

The subscription price of the new shares and the amount to be paid for the Company’s own shares must be entered in the invested unrestricted equity fund. 

Other terms and validity:

The Board of Directors decides on all other matters related to the authorizations. 

The authorizations are valid until the next Annual General Meeting from the decision of this Annual General Meeting.
 

Page last updated: 30 June 2025

Terms and conditions